SG155049A1 - Process for the manufacture of valsartan - Google Patents

Process for the manufacture of valsartan

Info

Publication number
SG155049A1
SG155049A1 SG200702272-6A SG2007022726A SG155049A1 SG 155049 A1 SG155049 A1 SG 155049A1 SG 2007022726 A SG2007022726 A SG 2007022726A SG 155049 A1 SG155049 A1 SG 155049A1
Authority
SG
Singapore
Prior art keywords
manufacture
valsartan
receptor antagonist
arb
salts
Prior art date
Application number
SG200702272-6A
Other languages
English (en)
Inventor
Donatienne Denni-Dischert
Hans Hirt
Dan Neville
Gottfried Sedelmeier
Anita Schnyder
Nadine Derrien
Daniel Kaufmann
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9944606&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG155049(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG155049A1 publication Critical patent/SG155049A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
SG200702272-6A 2002-09-23 2003-09-22 Process for the manufacture of valsartan SG155049A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0222056.4A GB0222056D0 (en) 2002-09-23 2002-09-23 Process for the manufacture of organic compounds

Publications (1)

Publication Number Publication Date
SG155049A1 true SG155049A1 (en) 2009-09-30

Family

ID=9944606

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200702272-6A SG155049A1 (en) 2002-09-23 2003-09-22 Process for the manufacture of valsartan

Country Status (30)

Country Link
US (3) US20060069268A1 (zh)
EP (2) EP1878729A1 (zh)
JP (2) JP4787498B2 (zh)
KR (2) KR20110015703A (zh)
CN (2) CN101153027B (zh)
AR (1) AR041360A1 (zh)
AU (1) AU2003270241B2 (zh)
BR (1) BR0314132A (zh)
CA (1) CA2502629A1 (zh)
CY (1) CY1107878T1 (zh)
DE (1) DE60317690T2 (zh)
DK (1) DK1546122T3 (zh)
EC (2) ECSP055695A (zh)
ES (1) ES2295623T3 (zh)
GB (1) GB0222056D0 (zh)
HK (1) HK1079771A1 (zh)
IL (1) IL167426A (zh)
MX (1) MXPA05003140A (zh)
MY (1) MY138618A (zh)
NO (2) NO20051970L (zh)
NZ (2) NZ566863A (zh)
PE (2) PE20091387A1 (zh)
PL (1) PL374862A1 (zh)
PT (1) PT1546122E (zh)
RU (2) RU2348619C2 (zh)
SG (1) SG155049A1 (zh)
SI (1) SI1546122T1 (zh)
TW (2) TWI338003B (zh)
WO (1) WO2004026847A1 (zh)
ZA (1) ZA200502159B (zh)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004013405T2 (de) * 2003-03-17 2009-05-07 Teva Pharmaceutical Industries Ltd. Polymorphe formen von valsartan
US7199144B2 (en) 2003-04-21 2007-04-03 Teva Pharmaceuticals Industries, Ltd. Process for the preparation of valsartan and intermediates thereof
EP1618097A1 (en) 2003-04-21 2006-01-25 Teva Pharmaceutical Industries Ltd Process for the preparation of valsartan
EP1556363A2 (en) * 2003-04-21 2005-07-27 Teva Pharmaceutical Industries Limited Process for the preparation of valsartan and intermediates thereof
GB0316546D0 (en) 2003-07-15 2003-08-20 Novartis Ag Process for the manufacture of organic compounds
GB0402262D0 (en) * 2004-02-02 2004-03-10 Novartis Ag Process for the manufacture of organic compounds
EP1661891A1 (en) * 2004-11-30 2006-05-31 KRKA, D.D., Novo Mesto A process for the synthesis of valsartan
GB0514206D0 (en) 2005-07-11 2005-08-17 Novartis Ag Organic compounds
ES2288376B1 (es) * 2005-10-20 2008-11-01 Inke, S.A. Procedimiento para la obtencion de intermedios utiles en la obtencion de un compuesto farmaceuticamente activo.
WO2007057919A2 (en) * 2005-10-25 2007-05-24 Alembic Limited An improved process for preparation of (s)-n-(1-carboxy-2-methyl-prop-1-yl)-n-pentanoyl-n-[2'-(1h-tetrazol-5-yl)biphenyl-4-ylmethyl]-amine
WO2008004110A2 (en) * 2006-07-03 2008-01-10 Aurobindo Pharma Limited Process for the preparation of the angiotensin ii antagonist valsartan
ES2315141B1 (es) * 2006-11-23 2009-12-22 Quimica Sintetica, S.A Procedimiento para la preparacion de cardesartan cilexetilo en forma cristalina.
CN101200455B (zh) * 2007-09-29 2010-08-18 泰兴市江神化工有限公司 沙坦类治疗高血压药物主环5-(4'-甲酰基联苯-2-基)-1h-四氮唑的制备方法
EP2090567A3 (en) 2008-02-13 2011-06-01 Ranbaxy Laboratories Limited Processes for the preparation of intermediates of valsartan
KR101012135B1 (ko) * 2008-12-18 2011-02-07 주식회사 대희화학 발사르탄 메틸 에스테르의 제조방법
EP2316821A1 (en) 2009-10-27 2011-05-04 Novartis AG Process for the manufacture of organic compounds
CN103052630A (zh) * 2010-08-03 2013-04-17 诺华有限公司 高度结晶的缬沙坦
CN102351804B (zh) * 2011-09-30 2013-07-31 浙江新赛科药业有限公司 一种缬沙坦消旋体的回收方法
CN103554047A (zh) * 2013-10-11 2014-02-05 镇江市高等专科学校 制备缬沙坦的方法
CN103923028B (zh) * 2014-05-04 2017-05-24 青岛雪洁助剂有限公司 一种缬沙坦甲酯的制备方法
CN104072433A (zh) * 2014-07-16 2014-10-01 南京正大天晴制药有限公司 一种缬沙坦的水解杂质化合物及其制备方法、检测方法和用途
CN104151199A (zh) * 2014-08-13 2014-11-19 苏州卫生职业技术学院 一种缬沙坦的合成方法
CN104844476B (zh) * 2015-04-03 2016-08-24 李凌 一种医药中间体联苯类化合物的合成方法
CN112014479A (zh) * 2019-05-28 2020-12-01 珠海润都制药股份有限公司 一种缬沙坦中正戊酰氯的检测方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2084801T3 (es) * 1990-02-19 1996-05-16 Ciba Geigy Ag Acil compuestos.
US5260325A (en) * 1991-08-19 1993-11-09 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking tertiary amides
FR2688503B1 (fr) * 1992-03-16 1994-05-06 Synthelabo Procede de preparation de derives de 2-(tetrazol-5-yl)-[1,1'-biphenyle].
EP0550313A1 (fr) * 1991-12-30 1993-07-07 Synthelabo Nouveaux dérivés de 2-(tétrazol-5-yl)-(1,1'-biphényle), leur préparation et leur utilisation comme intermédiaires de synthèse
US5284957A (en) * 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
JPH08165292A (ja) * 1993-10-07 1996-06-25 Techno Res Kk アデニン誘導体、その製造法及び用途
US5412102A (en) * 1994-05-27 1995-05-02 Syntex (U.S.A.) Inc. Processes for preparing 1-butyl-2-[2'-(2H-tetrazol-5-yl) biphenyl-4-ylmethyl]-1H-indole-3-carboxylic acid
US5468867A (en) * 1994-05-27 1995-11-21 Syntex (U.S.A.) Inc. Process for preparing1-butyl-2-[2'-(2H-tetrazol-5-yl)biphenyl-4-ylmethyl1-1H-indole-3-carboxylic acid
WO1996009301A1 (fr) * 1994-09-20 1996-03-28 Wakunaga Seiyaku Kabushiki Kaisha Procede de production d'un derive de n-biphenylmethylthiadiazoline ou un sel de celui-ci et son intermediaire de production
JPH11507625A (ja) * 1995-06-07 1999-07-06 アメリカン・ホーム・プロダクツ・コーポレイション ビフェニル誘導体の製造方法
CN1137887C (zh) * 2000-04-07 2004-02-11 常州四药制药有限公司 一种合成缬沙坦的改进方法
AU2001289672B2 (en) * 2000-07-19 2005-12-08 Novartis Ag Valsartan salts
GB0402262D0 (en) * 2004-02-02 2004-03-10 Novartis Ag Process for the manufacture of organic compounds

Also Published As

Publication number Publication date
PT1546122E (pt) 2008-02-14
NO20051970L (no) 2005-06-16
US20090111995A1 (en) 2009-04-30
RU2008133680A (ru) 2010-02-27
CN100357279C (zh) 2007-12-26
MY138618A (en) 2009-07-31
JP2010254709A (ja) 2010-11-11
JP2006502178A (ja) 2006-01-19
US20100249429A1 (en) 2010-09-30
EP1546122B8 (en) 2008-05-28
AU2003270241A1 (en) 2004-04-08
TWI338003B (en) 2011-03-01
KR20050057529A (ko) 2005-06-16
RU2412173C2 (ru) 2011-02-20
EP1878729A1 (en) 2008-01-16
TW200413337A (en) 2004-08-01
DK1546122T3 (da) 2008-03-03
WO2004026847A1 (en) 2004-04-01
TW201016673A (en) 2010-05-01
ECSP105695A (es) 2010-03-31
NZ538927A (en) 2008-05-30
US20060069268A1 (en) 2006-03-30
JP4787498B2 (ja) 2011-10-05
CN101153027B (zh) 2010-08-18
HK1079771A1 (en) 2006-04-13
PE20091387A1 (es) 2009-10-13
AR041360A1 (es) 2005-05-11
ZA200502159B (en) 2005-09-21
MXPA05003140A (es) 2005-06-22
CN101153027A (zh) 2008-04-02
EP1546122B1 (en) 2007-11-21
CN1688556A (zh) 2005-10-26
BR0314132A (pt) 2005-06-28
PE20050088A1 (es) 2005-02-21
PL374862A1 (en) 2005-11-14
RU2005112444A (ru) 2006-01-20
ECSP055695A (es) 2005-05-30
NO20110856L (no) 2005-06-16
CA2502629A1 (en) 2004-04-01
CY1107878T1 (el) 2013-06-19
TWI329106B (en) 2010-08-21
KR20110015703A (ko) 2011-02-16
RU2348619C2 (ru) 2009-03-10
ES2295623T3 (es) 2008-04-16
AU2003270241B2 (en) 2007-08-23
IL167426A (en) 2010-11-30
DE60317690T2 (de) 2008-10-30
NZ566863A (en) 2009-08-28
EP1546122A1 (en) 2005-06-29
DE60317690D1 (de) 2008-01-03
GB0222056D0 (en) 2002-10-30
SI1546122T1 (sl) 2008-04-30

Similar Documents

Publication Publication Date Title
SG155049A1 (en) Process for the manufacture of valsartan
MX2009004900A (es) Arilamidas sustituidas por tiazol u oxazol.
TNSN07195A1 (en) Potentiators of glutamate receptors
DE60239428D1 (zh)
MY149856A (en) Therapeutic agent for mesothelioma
TW200624426A (en) BACE inhibitors
TW200637822A (en) Process for the preparation of a 2-pyridylethylcarboxamide derivative
IL185731A0 (en) Purification of montelukast
TW200633981A (en) Process for the preparation of a 2-ethylaminopyridine derivative
TW200640912A (en) Novel processes for the preparation of a 2H-chromene
RS20050207A (en) Novel bicyclic inhibitors of hormone sensitive lipase
IL164787A0 (en) Tachykinin receptor antagonists
GEP20084494B (en) New heterocyclic carboxylic acid amide derivatives
TW200621756A (en) Method for manufacturing enantiomeric imidazole compounds
HK1079513A1 (en) Process for preparing intermediates
MY139159A (en) Method for synthesis of perindopril and its pharmaceutically acceptable salts
HK1094575A1 (en) A process for the preparation of phenyltetrazole derivatives
TN2012000154A1 (en) Process for the manufacture of organic compounds
NO20053208L (no) Metode for reduktiv dehalogenering.
SG149005A1 (en) Process for the preparation of thiazolopyrimidines
MY139348A (en) Method for synthesis of perindopril and its pharmaceutically acceptable salts
MY136288A (en) New process for the synthesis of perindopril and its pharmaceutically acceptable salts
WO2005054175A3 (en) New process for the preparation of nitrooxyderivatives of paracetamol
AU2003285428A1 (en) Pharmaceutical composition combining tenatoprazole and a histamine h2-receptor antagonist
WO2007017469A3 (en) Process for preparing an angiotensin ii receptor antagonist